MYMD - MyMD Pharmaceuticals, Inc. Stock Price, Fair Value and News

$1.33+0.02 (+1.53%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MYMD Price Action

Last 7 days

-5.3%

Last 30 days

-30.2%

Last 90 days

-35.6%

Trailing 12 Months

-92.7%

MYMD RSI Chart

MYMD Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

2.18

EV/EBITDA

-0.1

Price/Free Cashflow

-0.34

MYMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MYMD Fundamentals

MYMD Revenue

Revenue (TTM)

1.6M

MYMD Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

-147.72%

Earnings Growth (Qtr)

79.83%

MYMD Profitability

EBT Margin

-1500.20%

Return on Equity

-141.02%

Return on Assets

-98.4%

Free Cashflow Yield

-294.58%

MYMD Investor Care

Shares Dilution (1Y)

62.38%

Diluted EPS (TTM)

-12.95

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	2.0M	1.9M	1.8M	1.6M
2018	3.0M	2.4M	2.3M	1.7M
2017	3.1M	3.2M	3.3M	3.4M
2016	1.2M	2.1M	0	3.0M
2015	4.4M	3.0M	1.7M	305.6K
2014	2.8M	2.5M	2.7M	4.7M
2013	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

WEBSITE	mymd.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	9

MyMD Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for MyMD Pharmaceuticals, Inc.? What does MYMD stand for in stocks?

MYMD is the stock ticker symbol of MyMD Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MyMD Pharmaceuticals, Inc. (MYMD)?

As of Thu Oct 31 2024, market cap of MyMD Pharmaceuticals, Inc. is 3.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers.

Is MyMD Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether MYMD is over valued or under valued. Whether MyMD Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact MyMD Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYMD.

What is MyMD Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, MYMD's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 2.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYMD PE ratio will change depending on the future growth rate expectations of investors.